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Abstract
Antibody-antigen conjugates, which promote antigen-presentation by dendritic cells (DC) by means of targeted delivery of
antigen to particular DC subsets, represent a powerful vaccination approach. To ensure immunity rather than tolerance
induction the co-administration of a suitable adjuvant is paramount. However, co-administration of unlinked adjuvant
cannot ensure that all cells targeted by the antibody conjugates are appropriately activated. Furthermore, antigen-
presenting cells (APC) that do not present the desired antigen are equally strongly activated and could prime undesired
responses against self-antigens. We, therefore, were interested in exploring targeted co-delivery of antigen and adjuvant in
cis in form of antibody-antigen-adjuvant conjugates for the induction of anti-tumour immunity. In this study, we report on
the assembly and characterization of conjugates consisting of DEC205-specific antibody, the model antigen ovalbumin
(OVA) and CpG oligodeoxynucleotides (ODN). We show that such conjugates are more potent at inducing cytotoxic T
lymphocyte (CTL) responses than control conjugates mixed with soluble CpG. However, our study also reveals that the
nucleic acid moiety of such antibody-antigen-adjuvant conjugates alters their binding and uptake and allows delivery of the
antigen and the adjuvant to cells partially independently of DEC205. Nevertheless, antibody-antigen-adjuvant conjugates
are superior to antibody-free antigen-adjuvant conjugates in priming CTL responses and efficiently induce anti-tumour
immunity in the murine B16 pseudo-metastasis model. A better understanding of the role of the antibody moiety is
required to inform future conjugate vaccination strategies for efficient induction of anti-tumour responses.
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Introduction
Targeted delivery of antigen to DC is a very efficient strategy for
induction of antigen-specific T cell responses [1]. A number of C-
type lectin receptors (CLR) have been explored as target receptors
for antibody-mediated antigen delivery, including DEC205
(CD205), CD11c, Dectin-1 and -2, DNGR1 (Clec9A) and DCIR2
[2,3,4,5,6,7,8,9,10,11]. Targeted delivery of antigens to CLR leads
to efficient induction of humoral and cellular responses and has
been shown to be efficient in inducing anti-viral and anti-tumour
immunity [8,12,13,14,15,16,17]. However, while antibody-medi-
ated delivery of antigens to particular APC ensures efficient
antigen presentation, the presence of suitable adjuvants is required
to guarantee the appropriate activation and, consequently, T cell
stimulatory properties of the APC [18]. In the context of anti-
tumour immunity induction, synthetic mimics of viral pathogen-
associated molecular patterns (PAMP) are of particular interest
due to their ability to induce high levels of type I interferon (IFN-I)
and as a result of this to promote the initiation of CTL responses
[19,20].
So far, antibody-antigen conjugates have been employed in
combination with soluble adjuvants allowing for the activation of
APC populations that do not present the delivered antigen. This
could potentially lead to counterproductive side effects such as the
induction of autoimmune responses. Furthermore, TLR agonists
given systemically have been shown to recruit T cell populations to
the tissue depleting them from the circulating pool prior to
activation [21]. Other adverse effects that were observed upon
repeated administration of TLR7 and TLR9 agonists are
alterations in the structure of lymphoid follicles and splenomegaly
[22,23]. Strategies that reduce the likelihood of such adverse
effects would be beneficial in an immunotherapeutic context. We,
therefore, were interested in exploring antibody-mediated co-
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delivery of antigen and adjuvant to cross-priming DC in cis in
form of antibody-antigen-adjuvant conjugates. The co-delivery of
antigen and adjuvant would not only allow a reduction in the
adjuvant dose making unwanted side effects less likely, but also
would ensure that only APC that have taken up the delivered
antigen become activated. Furthermore, it has been shown that
co-delivery of antigen and adjuvant in form of antigen-adjuvant
conjugates or coated beads promotes antigen presentation [24,25].
To investigate whether antibody-antigen-adjuvant conjugates
are efficient in inducing CTL responses and anti-tumour
immunity, we generated such conjugates by biochemical cross-
linking of the TLR9 agonist CpG 1668 and the class I-restricted
peptide epitope of the model antigen OVA to DEC205-specific
antibody for a proof-of-principle study. Among the endosomal
TLR sensing viral nucleic acids, we chose to trigger TLR9 rather
than TLR3 or TLR7/8 for this study for technical and conceptual
reasons. CpG 1668 ODN represents a relatively small molecule of
defined size, unlike the TLR3 agonist polyI:C, and can be
synthesized in a modified form allowing for cross-linking via the
introduced sulfhydryl group. More importantly, the mouse CD8a+
DC subset specialized in cross-priming and primarily targeted by
DEC205 antibody expresses TLR9 and TLR3, but not TLR7 and
mouse TLR8 is thought to be non-functional [26,27,28]. In an
alternative approach, we generated equivalent conjugates by
biochemical conjugation of the TLR9 agonist to antigen fusion
antibody containing a heavy chain genetically fused to the full-
length antigen. We characterized these conjugates with regard to
their efficacy in inducing CTL response and anti-tumour
immunity and investigated their uptake by DC.
Results
Generation of Antibody-antigen-adjuvant Conjugates
Antibody-antigen-adjuvant conjugates for targeted co-delivery
of antigen and adjuvant to DEC205-expressing cells were
generated using the cross-linker sulfo-SMCC for conjugation of
a DEC205-specific antibody with the MHC-class I restricted
peptide epitope SIINFEKL of the model antigen OVA and the
TLR9 agonist CpG 1668 (DEC-OVA-CpG). Conjugates were
characterised upon SDS gel electrophoresis by sequential staining
of the gel with ethidium bromide and Comassie blue. As expected,
the size of the antibody-antigen-adjuvant conjugates was greater
than unconjugated antibody and consisted of a nucleic acid moiety
in addition to the protein as detected by ethidium bromide and
Comassie Blue staining, respectively (Figure S1A,B). The ethidium
bromide staining also confirmed that unconjugated CpG had been
successfully removed from the purified conjugate preparation
(Figure S1C).
The composition of the conjugates was determined by
photometric analysis of the nucleic acid content in combination
with the quantification of the biotin-labelled OVA peptide moiety
and the analysis of the protein concentration. An overview over
the molar composition of the different antibody-antigen-adjuvant
conjugates is given in Table 1. Overall, on average three CpG
ODN were conjugated to each antibody molecule, while the ratio
between antibody and peptide antigen was ranging between 1:1 to
1:3 for different DEC-OVA-CpG conjugate preparations.
DEC-OVA-CpG Conjugate Induces TLR9-dependent CTL
Priming
To test the ability of the DEC-OVA-CpG conjugate to induce
an antigen-specific immune response, mice were vaccinated by
footpad injection and in vivo CTL assays were performed six days
later. Vaccination with DEC-OVA-CpG conjugate induced a
CTL response in C57BL/6 mice with an average of 65.5%622.2
of peptide-pulsed target cells being killed (Figure 1A). Antigen-
specific target cell killing was largely reduced in TLR9 ko mice
indicating that CTL priming is dependent on innate immune
activation by the conjugate. Mice vaccinated with conjugate in the
presence of anti-CD40 antibody as alternative TLR-independent
adjuvant mounted a comparable CTL response independently of
TLR9 sufficiency.
DEC-OVA-CpG is More Efficient in Inducing CTL Priming
than Control Conjugate Co-injected with Soluble CpG
We were interested in evaluating the efficiency by which DEC-
OVA-CpG conjugate induces a CTL response in comparison to
an equivalent dose of a control conjugate co-injected with soluble
CpG ODN. To control for the size and the biochemical make-up
of the conjugates, we compared DEC-OVA-CpG to DEC-OVA-
GpC conjugate, the latter containing an ODN that does not
induce innate immune activation at the used dose [29]. The non-
stimulatory DEC-OVA-GpC control conjugate was co-injected
with increasing doses of soluble CpG ODN with 1.5 mg being
equivalent to the dose of CpG administered in conjugated form
with DEC-OVA-CpG. Interestingly, co-administration of increas-
ing doses of soluble CpG ODN resulted in a bell-shaped dose
response with 30 mg of co-injected CpG leading to less antigen-
specific killing of target cells than co-injection of 10 mg of the
TLR9 agonist (Figure 1B). High doses of CpG have been shown to
induce higher levels of the anti-inflammatory cytokine interleukin-
10, which could lead to suboptimal CTL priming [30]. More
importantly, vaccination with DEC-OVA-CpG induced a signif-
icantly higher average CTL response (55.0%628.6) than the
DEC-OVA-GpC control conjugate injected with the equivalent
amount of 1.5 mg soluble CpG ODN (31.6%616.8).
The frequency of interferon-c (IFNc)-producing CD8 T cells as
monitored by intracellular cytokine staining of ex vivo restimulat-
Table 1. Molar composition of generated conjugates.
Conjugate Molar composition
Antibody [mol] Antigen [mol] Adjuvant [mol]
DEC-OVA-CpG 1 2.261.1 3.961.1
DEC-OVA-GpC 1 3.261.7 2.861.3
DEC-OVA 1 2.861.1 N/A
iso1-OVA-CpG 1 1.660.4 3.461.1
iso2-OVA-CpG* 1 1.3 4.3
iso-OVA* 1 1.7 N/A
DEC-Fus-CpG= 1 2 5.360.18
DEC-Fus-CpG 1 2 10.461.3
iso-Fus-CpG 1 2 10.560.4
OVA-CpG= N/A 1 2.060.21
OVA-CpG N/A 1 1.160.14
The table depicts the composition of the generated conjugates regarding the
molar ratios of the antibody, the antigen (either SIINFEKL peptide or OVA
protein) and the nucleic acid adjuvant (CpG or GpC ODN) moieties. Where
several batches of conjugates were generated, mean values +/2 SD are
displayed.
*Only one batch of these conjugates was generated.
N/A - not applicable.
=These preparations of DEC-Fus-CpG and OVA-CpG were used for direct
comparison of these conjugates allowing for the application of similar amount
of adjuvant when normalizing for the antigen dose.
doi:10.1371/journal.pone.0040208.t001
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ed splenocytes from vaccinated mice, resulted in the same pattern
as observed for the in vivo CTL assay confirming that DEC-OVA-
GpC conjugate co-injected with an equivalent amount of soluble
CpG is less efficient in inducing a CD8 T cell response than DEC-
OVA-CpG conjugate (Figure 1C). Thus, despite the high
variability in CTL induction in mice vaccinated with DEC-
OVA-CpG, our data indicate that CpG co-delivered with the
antigen in cis in form of antibody-antigen-adjuvant conjugate is
more efficient in promoting CTL priming than antibody-antigen
conjugate co-administered with soluble CpG in trans.
Induction of Antigen-specific Killing by DEC-OVA-CpG
Conjugate is not Dependent on DEC205-mediated
Targeting
Antibody-antigen conjugates targeting DEC205 on antigen-
presenting DC confer immunity in a DEC205-dependent manner
[3]. Consequently, antibody-antigen conjugates generated with
isotype control antibody are inefficient in inducing an antigen-
specific immune response [2,3]. To investigate the requirement for
DEC205-targeted delivery of the antibody-antigen-adjuvant con-
jugates, we compared the induction of CTL responses in DEC-
OVA-CpG vaccinated mice to those in mice immunised with
equivalent conjugates generated with an isotype control antibody
(iso1-OVA-CpG). Surprisingly, vaccination with iso1-OVA-CpG
resulted in excellent antigen-specific killing of target cells, even
exceeding the response induced by the DEC-OVA-CpG conjugate
(Figure 2A). To confirm this unexpected result, we tested an
additional control conjugate generated with a different isotype
control antibody (iso2-OVA-CpG; Figure 2B). Also in this case,
the CTL response was stronger for the isotype control antibody-
containing conjugate than for the DEC205-targeted antibody-
antigen-adjuvant conjugate. Endotoxin levels of all conjugates
were below 10 U/mg suggesting that endotoxin contamination
was not responsible for the increased CTL induction observed
with the isotype control antibody-containing conjugates. The
results, therefore, suggest that targeting of antibody-antigen-
adjuvant conjugates to DEC205 is reducing rather than enhancing
the immunogenicity of the tested antibody-antigen-adjuvant
conjugates. This effect is, however, not observed for the
corresponding antibody-antigen conjugates co-injected with solu-
ble TLR9 agonist (Figure S2) implicating that the addition of a
nucleic acid moiety alters the functional properties of the
conjugates.
To further investigate this, we blocked DEC205-mediated
conjugate delivery by co-injecting a high dose of unconjugated
anti-DEC205 antibody together with DEC-OVA-CpG conjugate.
Unconjugated DEC205 antibody decreased antigen-specific target
cell killing in control mice that were vaccinated with DEC-OVA
Figure 1. CTL priming by DEC-OVA-CpG conjugate is TLR9-
dependent and more efficient than co-injection of control
conjugate and soluble CpG. (A) C57BL/6 and TLR92/2 mice were
immunised into the footpad with 6–8 mg of DEC-OVA-CpG conjugate
with or without 25 mg anti-CD40 antibody or received PBS injections. At
day 5 after immunisation, target cells were injected intravenously and
the following day, antigen-specific killing was analysed by flow
cytometric analysis of splenocyte preparations. The depicted data are
pooled from three independent experiments using three different
conjugate preparations. (B) C57BL/6 mice were immunised into the
footpad with 8 mg of DEC-OVA-CpG or DEC-OVA-GpC control conju-
gate. The control conjugate was administrated alone or in combination
with increasing doses of soluble S-CpG as indicated. 1.52 mg co-injected
soluble S-CpG equals the amount of S-CpG delivered in conjugated
form with 8 mg of DEC-OVA-CpG. Control mice were injected with PBS.
At day 5 after immunisation, target cells were injected and the in vivo
CTL assay was analysed the following day as described above. (C)
Additionally, splenocytes were cultured over night in the presence of
1 mM SIINFEKL peptide and the frequency of IFNc-producing CD8+ T
cells was determined the next day after 3 hours of incubation in the
presence of Brefeldin A. Data are pooled from four independent
experiments (A-C). Each dot represents the CTL response or the
frequency of IFNc-producing CD8+ T cells of an individual mouse, while
the average values for each group are depicted as a bar.
doi:10.1371/journal.pone.0040208.g001
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conjugate in the presence of soluble CpG ODN indicating that the
competition for DEC205 reduced DEC205-specific delivery of this
conjugate (Figure 2C). In contrast, in mice vaccinated with DEC-
OVA-CpG conjugate, CTL-mediated killing was improved when
DEC205-mediated delivery of the conjugate was impaired by the
presence of unconjugated DEC205-specific antibody and reached
levels observed for iso-OVA-CpG conjugate (Figure 2C). As
expected, CTL induction by iso-OVA-CpG conjugates was
unaffected by the presence of DEC205-specific antibody
(Figure 2C). These blocking experiments support the conclusion
that DEC205-mediated targeting of the tested conjugates reduces
rather than enhances their immunogenicity.
The SIINFEKL Peptide and the Nucleic Acid Moieties
Influence the Binding of Antibody-antigen-adjuvant
Conjugates
To investigate how the addition of a nucleic acid moiety
influences the binding of the conjugates, we stained CD11c-
enriched splenocytes with antibody-antigen and antibody-antigen-
adjuvant conjugates or unconjugated antibody, which were either
directly fluorescently labelled or indirectly detected with secondary
reagents as indicated. Direct and indirect detection of conjugates
produced the same staining pattern ruling out the possibility that a
contamination with fluoescently labelled antibody not conjugated
Figure 2. DEC205-independent CTL induction by antibody-antigen-adjuvant conjugates. (A–C) C57BL/6 mice were immunised into the
footpad with 8 mg of DEC-OVA-CpG, iso-OVA-CpG or DEC-OVA conjugate. In (C) immunisations took place in the presence or absence of 200 mg of
anti-DEC205 antibody and DEC-OVA was co-injected with 10 mg soluble CpG ODN. Control mice received PBS injections. At day 5 or 6 after
immunisation, target cells were injected intravenously. The following day, the in vivo CTL assay was analysed by flow cytometry. Data in (A) are
pooled from 7 experiments while the graphs in (B and C) contain data from 2 independent experiments. In (C) a one-tailed Student’s t-test was used
for statistical analysis.
doi:10.1371/journal.pone.0040208.g002
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to antigen or CpG ODN, or that the addition of an additional
moiety in form of the fluorescent dye skewed the binding profile of
the conjugates (Figure S3). In addition, dose titrations for the
different conjugates were performed to exclude the possibilty that
saturating doses mask differences in the strength of binding (Figure
S3). Interestingly, staining with DEC205-specific antibody was
saturated at doses from 10 nM upwards, whereas saturation of
binding of OVA peptide-containing conjugates was observed for
doses from 90 nM upwards (Figure S3). This suggests that
DEC205-specific antibody-containing conjugates may lose some
of their binding capacity due to the conjugation process. In all
subsequent staining experiments a dose of 30 nM conjugate was
used to exclude saturation of DEC205-mediated binding on
CD8a+ DC.
As expected, DEC205-specific antibody predominantly bound
to splenic CD8a+ DC confirming that these cross-priming DC
express high levels of DEC205 (Figure 3A). In contrast, DEC-
OVA conjugate stained CD8a+ and CD8a2 DC subsets as did iso-
OVA conjugate (Figure 3A). However, DEC-OVA conjugate
bound more efficiently to CD8a+ DC than to the CD8a- DC
subsets, whereas iso-OVA conjugate showed only weak binding to
these DC subsets irrespective of DEC205 expression (Figure 3A).
The binding of DEC-OVA-CpG conjugate to CD8a+ and CD8a2
DC was improved as compared to the binding of DEC-OVA
conjugate and was almost indistinguishable from binding of the
equivalent isotype control conjugate (Figure 3A).
In order to determine the extent of DEC205-mediated binding
of the conjugates, we performed blocking experiments with
unlabelled DEC205-specific antibody. DEC-OVA and the corre-
sponding isotype control antibody-containing conjugates showed
low levels of DEC205-independent binding to CD8a+ and CD8a2
DC. However, the DEC-OVA conjugate retained the capacity to
bind to DEC205 as shown by the partial block in conjugate
binding in the presence of excess DEC205 antibody (Figure 3A).
To investigate whether the binding of DEC-OVA and iso1-OVA
conjugate was mediated by the peptide moiety, we performed
additional blocking experiments with SIINFEKL peptide and also
tested equivalent conjugates with a longer OVA-specific peptide
referred to as OVAlong. Surprisingly, the OVAlong-containing
antibody-antigen conjugates did not mediate DEC205-indepen-
dent binding (Figures S3 and S4) suggesting that peptide-mediated
binding of DEC-OVA and iso1-OVA conjugate is a SIINFEKL-
specific artefact. Furthermore, blocking with unconjugated
SIINFEKL peptide led to a partial reduction in binding of
DEC-OVA and to a complete reduction in binding of iso1-OVA
conjugate by CD8a2 DC supporting the notion that SIINFEKL
peptide mediates binding of these antibody-antigen conjugates to
DC (Figure S4A). Blocking of DEC205- and SIINFEKL-mediated
binding of DEC-OVA conjugate, both only led to a partial
reduction in conjugate binding by CD8a+ DC supporting the
conclusion that both conjugate moieties mediate binding inde-
pendently (Figures 3A and S4A). In contrast, binding of DEC-
OVAlong was completely blocked in the presence of blocking
DEC205 antibody (Figure S4A).
For conjugates containing a CpG moiety, blocking experiments
with DEC205 antibody or SIINFEKL peptide were ineffective or
only slightly reduced conjugate binding (Figure S4A). For further
characterisation of the binding modalities of our conjugates, we
also performed blocking experiments with polydT17-G12 ODN in
order to inhibit CpG-mediated binding. Conjugates without the
CpG moiety showed no reduction in binding in the presence of
polydT17-G12 in contrast to antibody-antigen-adjuvant conju-
gates (Figure S4A). We chose polydT17-G12 ODN for blocking of
CpG-mediated binding, since it lacks immunostimulatory activity
at high concentrations unlike GpC ODN. Interestingly, polydT17-
G12 partially inhibited binding of DEC-OVA-CpG on CD8a2
but not on CD8a+ DC probably due to the presence of DEC205-
mediated binding by the latter DC subset (Figure S4A). However,
the reduction in binding of CpG-containing DEC-OVA-CpG and
iso1-OVA-CpG conjugates by CD8a2 DC was not absolute, most
likely due to the presence of SIINFEKL-mediated binding.
While these binding studies suggest that the addition of the
SIINFEKL peptide moiety, as well as the addition of a nucleic acid
moiety influence the binding of the conjugates, it is unclear how
this affects uptake in vivo. To investigate this, we injected
fluorescently labelled antibodies, antibody-antigen and antibody-
antigen-adjuvant conjugates into C57BL/6 mice by footpad
injection and analysed uptake of the fluorescent marker by
CD11c+ cells in the draining lymph node. Unfortunately, we could
not discriminate between the different lymph node DC popula-
tions, since the injection of DEC205-specific antibody leads
uniformly to the down-regulation of DEC205 on the otherwise
DEC205+ DC subsets. While DEC205-specific antibody efficiently
stains CD8a+ lymph node DC, isotype control antibody did not as
efficiently associate with this DC population (Figure 3B). Similar to
what had been observed in vitro, antibody-antigen conjugates
were efficiently taken up by CD8a+ DC and CD8a2 DC in vivo
irrespective of the antibody specificity (Figure 3B). Interestingly,
levels of uptake of DEC-OVA-CpG conjugate by a subpopulation
of CD8a+ DC was equivalent to the uptake of DEC205-specific
antibody and DEC-OVA conjugate, but the other subpopulation
of CD8a+ DC stained only poorly for the fluoresecent dye.
However, a clear difference in uptake between DEC-OVA-CpG
and iso1-OVA-CpG conjugates was observed suggesting that upon
addition of a CpG moiety the conjugates regain some level of
targeting specificity. These data confirm that the conjugation of
SIINFEKL peptide and CpG ODN to antibody for the generation
of antibody-antigen-adjuvant conjugates alters the binding pattern
and the uptake of these conjugates. Similar results were obtained
for antibody-antigen-adjuvant conjugates generated with non-
stimulatory GpC ODN (data not shown). However, the difference
in uptake between antibody-antigen-adjuvant conjugates contain-
ing DEC205-specific versus isotype control antibody does not
correlate with their efficiency in CTL induction.
The finding that the addition of the SIINFEKL peptide alters
the binding specificity of the conjugates was particularly surprising.
To exlude SIINFEKL-mediated binding of conjugates, we
performed similar experiments using antigen fusion antibody
containing full-length OVA fused to the constant region of the
antibody heavy chain [3]. As expected from our experiments with
DEC-OVA and DEC-OVAlong conjugates, genetically engi-
neered DEC-OVA fusion antibody (DEC-Fus) showed a prefer-
ence for binding to DEC205-high CD8a+ DC in vitro and did not
bind to the CD8a2 DC subsets (Figure 3C). Isotype control
antibody-antigen fusion protein failed to bind to any of the DC
subsets with great efficiency (Figure 3C). We produced second-
generation antibody-antigen-adjuvant conjugates by biochemically
linking CpG ODN to antigen fusion antibodies (Figure S5). The
CpG-containing fusion antibody conjugates (DEC-Fus-CpG and
iso-Fus-CpG) bound equally well to all CD8a2 and CD8a+ DC
irrespective of the antibody specificity (Figure 3C). A dose titration
of the conjugates revealed that their capacity to bind CD8a+ DC
was identical to that of peptide-containing conjugates and
saturating doses were reached at 90 nM and above (Figure S3).
Due to the absence of peptide-mediated binding, DEC-Fus
conjugate binding was entirely blocked by DEC205-specific
antibody as expected (Figures 3C and S4B). As seen before for
DEC-OVA-CpG and iso1-OVA-CpG conjugates, binding of
Antibody-Antigen-Adjuvant Conjugates
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CpG-containing conjugates is partially mediated by the nucleic
acid moiety and is reduced in the presence of polydT17-G12
ODN (Figure S4B). When fluorescently labelled antigen fusion
antibodies (DEC-Fus and iso-Fus) were injected into the footpad of
mice, DEC205-specific delivery of antigen fusion antibody to
CD8a+ DC was observed (Figure 3D). In contrast, the antigen
fusion antibodies conjugated to CpG ODN (DEC-Fus-CpG and
iso-Fus-CpG), bound to CD8a+ DC irrespective of the antibody-
specificity and were equally well delivered to CD8a2 DC
(Figure 3D and data not shown).
In summary, the data show that the addition of a CpG moiety
to antibody-antigen conjugates alters their binding properties and,
thus, may also make the targeted delivery of the antigen partially
independent of the antibody component.
Antibody-antigen-adjuvant Conjugates are More Efficient
in Priming CTL than the Equivalent Antigen-adjuvant
Conjugates Despite their Partial Antibody-independent
Binding
To determine the extent to which the fusion antibody
conjugates induce antigen-specific CTL-mediated killing, we
vaccinated mice and determined antigen-specific target cell killing
by in vivo CTL assay. As expected, DEC205-specific antigen
fusion antibody co-injected with soluble CpG ODN was efficient
in inducing a CTL response in contrast to antigen fusion isotype
control antibody (Figure 4). CpG-containing conjugates generated
with isotype control antigen fusion antibody induced significantly
lower levels of CTL-mediated killing than DEC205-targeted
conjugate (Figure 4). This result suggests that exclusive CpG-
mediated targeting of antigen fusion antibody-CpG conjugates is
less efficient in promoting CTL induction than in combination
with DEC205-mediated targeting.
To further consolidate the hypothesis that antibody-mediated
targeting of DEC205 by conjugates containing a CpG moiety
contributes to CTL priming, we compared antibody-antigen-
adjuvant conjugates with antigen-adjuvant conjugates. To
address this question, we generated conjugates of OVA protein
and CpG ODN (OVA-CpG) by biochemical linkage with the
cross-linker sulfo-SMCC [24,31,32]. The calculated molecular
weight of the OVA-CpG conjugate is 5 times smaller than the
molecular weight of the corresponding antibody-antigen-adju-
vant conjugate (DEC-Fus-CpG) and the fusion antibody
conjugate contains two mol of antigen per mol of conjugate
in contrast to one mol of antigen per mol of antigen-adjuvant
conjugate. We injected mice with different, but comparable
doses of these conjugates normalising for the amount of antigen
applied and evaluated the induced CTL responses. At a dose of
2 mg, DEC-Fus-CpG leads to average antigen-specific killing of
78.3% +/225.1 in vaccinated mice (Figure 5A). A dose of
0.8 mg OVA-CpG provides the equivalent amount of antigen
(14 pmol) and a similar dose of adjuvant compared to 2 mg of
the antibody-antigen-adjuvant conjugate, but only leads to
40.17% +/234.3 of target cell killing (Figure 5A). When a
higher equivalent dose (28 pmol of antigen) is used for
vaccination, OVA-CpG and DEC-Fus-CpG induce comparable
levels of antigen-specific killing (Figure 5A).
Next, we tested these conjugates for the induction of anti-
tumour immunity in a prophylactic B16 pseudo-metastasis model.
Vaccination with the higher dose of Dec-Fus-CpG and OVA-CpG
conjugates delivering 28 pmol of antigen protected the mice from
tumour growth. However there was a small but significant
difference in the level of protection with the antibody-containing
conjugates being more effective in inducing anti-tumour immunity
(Figure 5B). However, when vaccinating the mice with the lower
dose of antigen, strong inter-experimental variability was ob-
served. Remarkably, vaccination with 0.8 mg of OVA-CpG
conjugate (14 pmol of antigen) failed to protect the mice from
tumour growth in one of the two experiments, even though this
dose led to a measurable CTL response (Figure 5). Interestingly,
1 mg of DEC-Fus-CpG conjugate equalling a dose of 7 pmol of
antigen was still sufficient to largely protect the mice from tumour
challenge, despite the fact that at this dose CTL activity was highly
variable with 44.5% +/243.6 of antigen-specific killing (Figure
S6).
We also evaluated the therapeutic potential of the conjugates in
the B16 pseudo-metatstasis model and treated mice 6 days after
tumour cell inoculation. At an antigen dose of 28 pmol, mice
vaccinated with either conjugate were partially protected from
tumour challenge with regard to the number of visible tumour
nodules (Figure 5C; p,0.05 for DEC-Fus-CpG and OVA-CpG
versus mock, respectively). At the lower antigen dose of 14 pmol,
the number of tumour nodules was not significantly reduced
compared to untreated mice (Figure 5C). However, the treatment
showed clear beneficial influence on the size of the tumour
nodules, which were very small in comparison to the nodules
observed in untreated mice (Figures 5D and S7). The reduction in
the size of the tumour nodules was more prominent in mice
vaccinated with Dec-Fus-CpG conjugates as compared to OVA-
CpG conjugates. Unfortunately, this observation was not quanti-
fiable.
Taken together, these data imply that the targeted delivery of
antigen and adjuvant using a DEC205-specific antigen fusion
antibody leads to robust priming of CTL and anti-tumour
immunity induction. Antibody-antigen-adjuvant conjugates tar-
geted to DEC205 were superior in inducing antigen-specific killing
compared to untargeted OVA-CpG conjugates. However, in the
prophylactic and the therapeutic B16 pseudo-metastasis model,
the antibody-containing conjugates were only slightly more
efficient in preventing tumour growth. It will be interesting to
evaluate whether the difference between the conjugates depends
on the residual targeting specificity of the antibody-antigen-
adjuvant conjugates.
Figure 3. Addition of a CpG ODN moiety alters binding and in vivo targeting of antibody-antigen conjugates. (A, C) CD11c-enriched
splenocytes from C57BL/6 were stained with 30 nM DyLight488-labelled antibody or conjugate in combination with CD11c- and CD8a-specific
antibodies. For blocking of DEC205-mediated conjugate binding, unlabelled DEC205-specific antibody (100 mg/ml) was added to the staining mix.
Binding of antibody or conjugate was analysed by flow cytometry gating on CD8a+ versus CD8a2 DC. The overlays show staining with DEC205-
specific antibody (DEC) or the different conjugates in the absence (black histograms) or in the presence of blocking DEC205 antibody (red
histograms) as indicated. Staining with isotype control antibody is shown as solid grey histograms. (B, D) DyLight488-labelled antibodies and
conjugates were injected into the footpad of C57BL/6 mice. Single cell suspensions from popliteal lymph nodes were prepared 6 hours later and
splenocytes suspension were analysed directly (B) or after enrichment of MHC class II+ cells by magnetic cell sorting (D). Cells were stained with
CD11c- and CD8a-specific antibodies and the percentage of DyLight488+ CD8a+ DC was determined by flow cytometry. Background staining of
CD8a+ DC from mice injected with labelled isotype control antibody (B) or PBS (D) is shown as solid grey histograms overlayed with DyLight488-
staining of CD8a+ DC from mice that received labelled DEC205-specific antibody or conjugates as indicated (black histograms). Data are
representative of at least 2 independent experiments.
doi:10.1371/journal.pone.0040208.g003
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Discussion
The aim of this study was to generate conjugates for the targeted
co-delivery of antigen and adjuvant to DEC205+ DC for the
induction of anti-tumour immune responses. However, when
comparing conjugates generated with anti-DEC205 specific
antibody to equivalent conjugates containing isotype control
antibody, it became evident that the CpG ODN moiety mediates
binding to DEC2052 cells, thus partially overriding antibody-
mediated targeting of DC. Interestingly, DEC205-independent
CpG-mediated delivery of the conjugates containing isotype
control antibody led to the induction of strong CTL responses
for conjugates generated with antigen-specific peptide biochemi-
cally linked to the antibody, whereas in the case of conjugates
containing antigen fusion antibody the level of CTL killing
induced was minimal and significantly lower than for equivalent
conjugate containing DEC205-specific antigen fusion antibody.
Our data suggest that SIINFEKL peptide-mediated uptake in
combination with CpG-mediated uptake of the conjugates rather
than CpG-mediated uptake alone overrides the DEC205-mediat-
ed targeting and drives very efficient CTL induction by isotype
control containing conjugates. Since the observed peptide-
mediated uptake of conjugates represents a peptide-specific
artefact and was not detected for conjugates containing peptides
other than SIINFEKL or full-length OVA as present in antigen
fusion antibody (Figure 3 and data not shown), we did not further
investigate this phenomenon. What our data clearly show is that
genetic fusion of the antigen is favourable over biochemical linkage
for the generation of well-defined antibody-antigen conjugates and
in order to avoid peptide-mediated effects. The CpG-containing
conjugates generated with antigen fusion antibody were overall
more efficient in inducing CTL responses and anti-tumour
immunity and did so at lower doses as compared to the conjugates
generated with SIINFEKL peptide (data not shown).
In the absence of SIINFEKL peptide-mediated binding, CpG-
mediated delivery of antibody-antigen-adjuvant conjugates does
not efficiently promote the induction of strong CTL responses as
evidenced by the antigen fusion isotype control antibody-CpG
conjugates. Firstly, this result suggests that despite of CpG-
mediated conjugate delivery, part of the conjugate is delivered in a
DEC205-dependent manner to cross-priming DC. Secondly, it
supports the notion that DEC205-mediated delivery of antigen
and in our case also of the adjuvant promotes cross-priming.
It also should be noted that the actual cross-priming DC
population may be a subfraction of the mouse CD8a+ DC subset.
Furthermore, CD8a expression is not a sufficient marker for
distinguishing the different DC subsets in lymph nodes and
comparing the uptake of the different conjugates by lymph node
CD8a+ DC may be misleading [33]. This would explain why
DEC-Fus-CpG conjugate is more efficient in inducing a CTL
response than iso-Fus-CpG despite the fact that both conjugates
are equally well taken up by CD8a+ DC in the draining lymph
node. Another possible explanation for this observation is that
DEC205-mediated conjugate uptake destines the antigen to a
different fate than CpG-mediated delivery with the former
promoting cross-priming more efficiently than the latter. In this
context it is interesting to note that mannose receptor-mediated
uptake has been described to advance cross-presentation of
antigen in DC [34], since it transports the antigen into an early
endosomal compartment from which cross-presentation can occur
[35]. Like mannose receptor, DEC205 is involved in antigen
processing and may favour uptake into early endosomes [36] and
promote cross-presentation [37]. In contrast CpG, which has been
described to mediate uptake via macrophage scavenger receptor
type A [38,39,40], may deliver the conjugates to an endosomal
compartment that is specialised in generating peptides for
presentation on MHC class II.
Figure 4. CTL induction by antigen fusion antibody-adjuvant conjugate is promoted by DEC205-mediated targeting. C57BL/6 mice
were immunised into the footpad with 8 mg of ovalbumin fusion antibody either containing DEC205-specific (DEC-Fus) or isotype control antibody
(iso-Fus) in combination with 10 mg soluble CpG ODN. Alternatively, mice were immunised with 8 mg of CpG-containing conjugates generated with
Dec205-specific (DEC-OVA-CpG) or isotype control antigen fusion antibody (iso-Fus-CpG). Control mice received PBS injections. At day 5 after
immunisation, in vivo CTL assays were performed by injecting target cells intravenously and by analysing antigen-specific killing the following day.
The depicted data are pooled from 3–5 independent experiments with three mice per group for each experiment. Each dot represents the CTL
response of an individual mouse. The average antigen-specific killing for each group is depicted as a bar.
doi:10.1371/journal.pone.0040208.g004
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It will be interesting to identify whether antibody-antigen-
adjuvant conjugates targeting DEC205 and equivalent untargeted
antigen-adjuvant conjugates show differences in their pharmaco-
kinetics and whether these differences are entirely due to the
difference in size or are mediated completely or in part by the
antibody. The DEC205-specific ovalbumin fusion antibody used
in this study does not allow for FcR binding [18,41]. Thus, FcR-
mediated effects are unlikely to contribute to the observed
difference in CTL induction between the antibody-antigen-
adjuvant and the antigen-adjuvant conjugates.
An alternative strategy for CLR-targeted co-delivery of antigen
and adjuvant to specific DC is the use of liposomes [42] or
biodegradable nanoparticles [43,44] coated with CLR-specific
antibodies and encapsulated with the antigen and the adjuvant.
The encapsulated adjuvant does not alter the targeting specificities
of these vaccines and the co-delivery of antigen and adjuvant
clearly has advantages over the use of soluble adjuvant as shown
for the targeted nanoparticle-based vaccine [44]. However, it is
currently unclear how well such CLR-targeted liposome- or
nanoparticle-based vaccines compare to an antibody-antigen
conjugate approach with regard to the efficacy of the vaccination.
Only direct comparison of the different approaches will allow an
assessment of which strategy ultimately leads to the most efficient
anti-tumour immunity induction. Until this is clarified it remains
unclear which strategy will prove most promising in a clinical
setting. Currently, it can not be excluded that antibody-antigen-
adjuvant conjugates represent a more efficient means for inducing
anti-tumour immunity despite their partial lack in antibody-
mediated targeting specificity.
A better understanding of the underlying mechanisms that lead
to successful delivery of conjugates to the cross-priming DC subset
is required to inform optimal conjugate design. From our study,
we conclude that conjugation of the adjuvant to antigen-fusion
antibody can offer advantages over using soluble adjuvant despite
the partial loss in targeting specificity.
Materials and Methods
Ethics Statement
All animal experiments were undertaken in accordance with
UK governmental regulations (Animal Scientific Procedures Act
1986) under the project licences PPL 70/6317 and 70/7131.
Ethics approval for the study was granted by the Guy’s Ethical
Review Process committee. To minimise suffering of animals in
particular upon implantation of tumour cells we followed the
UKCCCR guidelines for the Welfare of Animals in Experimental
Neoplasia [45].
Figure 5. Antigen fusion antibody-adjuvant conjugate is
superior in inducing anti-tumour immunity in comparison to
antigen-adjuvant conjugate. C57BL/6 mice were immunised into
the footpad with comparable doses of antigen (14 pmol and 28 pmol)
in form of fusion antibody conjugated to CpG (DEC-Fus-CpG) or
antigen-adjuvant conjugate (OVA-CpG). Control mice were injected
with PBS. (A) At day 5 after immunisation, in vivo CTL assays were
performed by intravenous injection of target cells. Antigen-specific
killing of target cells was analysed the following day. The depicted data
are pooled from 4 independent experiments using two different
conjugate batches for each conjugate type. (B) 30 days post
immunisation, OVA-expressing B16 melanoma cells were injected
intravenously and 18 days later, the number of lung nodules was
determined. Data from two independent experiments are shown. (C)
For the therapeutic tumour model, mice were inoculated intravenously
with OVA-expressing B16 melanoma cells and 6 days later mice were
vaccinated by footpad injection. The number of tumour nodules was
evaluated 18 days after tumour cell injection. Data from three
independent experiments are shown. Each symbol representing an
individual mouse while the average antigen-specific killing (A) or
number of lung nodules (B and C) for each group is depicted as a bar.
(D) Representative photographs of the fixed left upper lung lobes of
mice treated with 28 pmol of conjugates as described in (C) to
demonstrate that the number of tumour nodules was not necessarily
reduced upon treatment, but that tumour nodules were much smaller
than in mock-treated mice especially upon vaccination with DEC-Fus-
CpG conjugate.
doi:10.1371/journal.pone.0040208.g005
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Oligonucleotides and Peptides
The phosphorothioate ODN CpG 1668 (TCCAT-
GACGTTCCTGATGCT) and GpC 1668 (TCCAT-
GAGCTTCCTGATGCT) were purchased from either MWG
Eurofins (Ebersberg, Germany) or Thermo Scientific (Loughbor-
ough, UK) with a thiol modification (S-CpG and S-GpC).
Unmodified CpG 1668 (CpG) and phosphorothioate ODN
polydT17-G12 (T17G12) were from MWG.
Peptides were synthesized by Cancer Research UK (London,
UK) or Thermo Scientific. The MHC class I-restricted OVA-
specific peptide SIINFEKL (OVA257–264) was synthesized in
unmodified form or with an added cysteine and biotin group at
the C terminus (SIINFEKL-C-biotin). Likewise, the 36 amino acid
long peptide OVAlong containing the SIINFEKL epitope plus the
MHC class II-restricted OVA epitope (OVA323–339) was obtained
including a cysteine and a biotin group at the C-terminus.
Generation of Antibody-antigen-adjuvant Conjugates
The antibodies were purified from the supernatant of NLDC-
145 (anti-mouse DEC205-specific rat IgG2a antibody), Y13-238
(anti-human p21-specific rat IgG2a antibody) and SFR3-DR5
(anti-human HLA-DR5-specific rat IgG2b antibody) hybridoma
cells, all of which were purchased from LGC standards
(Teddington, UK). Antibody purification was performed using
the Montage Antibody Purification kit from Millipore (Watford,
UK). Antigen fusion antibody was isolated from the supernatant of
transiently transfected 293 T cells as described [18]. 293 T cells
were obtained from Sophia Karagiannis’ group at King’s College
London [46].
Antibody and antigen fusion antibody was treated with
sulfosuccinimidyl 4-[N-maleimidomethyl]cyclohexane-1 carboxyl-
ate (sulfo-SMCC from Thermo Scientific) for 30 min at room
temperature and excess crosslinker was subsequently removed
using Amicon Ultra-4 filter units with a 10 kD cut-off (Millipore).
S-CpG or S-GpC ODN was added to the activated antibody at a
molar ratio of 12.5:1. After an incubation of 20 min, peptide
containing a C-terminal cysteine and biotin group was added to
the antibody, but not to antigen fusion antibody, at a molar ratio
of 6.25:1 and the solution was incubated for another 70 min at
room temperature. The generated conjugates were concentrated
using Amicon Ultra-4 filter units (10 kD cut-off), followed by gel-
filtration using a Sephacryl S-200 column (GE Healthcare,
London, UK). The optical density at a wavelength of 260 nm
and 280 nm of the collected fractions was determined and
fractions containing conjugate were pooled. Conjugate was
concentrated using Amicon Ultra-4 filter units (10 kD cut-off)
and sterile filtered (Ultrafree-MC, Millipore). Antigen-adjuvant
conjugates were generated as described [24].
The conjugates were characterised by SDS gel electrophoresis
on Tris-glycin gradient gels (4–20%; Invitrogen, Paisley, UK) in
combination with staining in ethidium bromide solution for
nucleic acid detection followed by staining in Coomassie blue
solution for protein detection. The CpG content of the conjugates
was determined photometrically at a wavelength of 260 nm using
a mixture of antibody and soluble S-CpG/S-GpC ODN as
standard curve. The content of biotinylated peptide was estab-
lished using the Fluoreporter assay from Invitrogen. Furthermore,
conjugates were tested for endotoxin contamination in a Limulus
amoebocyte lysate assay (Lonza, Slough, UK). The endotoxin
concentration was consistently below 10 U/mg protein.
Mice
C57BL/6 mice were obtained from Harlan UK (Bicester, UK),
B&K Universal Ltd (Hull, UK) or Charles River (Margate, UK).
TLR9 KO mice were bred at the biological service unit at King’s
College London. Experimental procedures were performed on 6–
12 week old mice and animals were sex- and age-matched for
individual experiments.
Binding Assays
CD11c+ DC were enriched from collagenase D/DNase-
digested (Roche, Weleyn Garden City, Hertfordshire, UK)
splenocyte preparations by positive selection with MACS beads
(Miltenyi, Bergisch Gladbach, Germany). CD11c-enriched DC
were stained with DyLight 488-labelled or unlabelled DEC205-
specific or rat IgG2a isotype control antibodies or conjugates
(0.3 nM–120 nM) in the presence of fluorescently labelled CD11c-
and CD8a-specific antibodies (BD Bioscience, Oxford, UK) for
30–60 minutes on ice. In case of unlabelled antibodies or
biotinylated peptide-containing conjugates, cells were subsequent-
ly stained with PE-labelled streptavidin (BD Bioscience). In case of
unlabelled OVA fusion antibodies and conjugates, samples were
indirectly stained with polyclonal biotinylated rabbit anti-OVA
antibody (Abcam, Cambridge, UK) followed by PE-labelled
streptavidin. Samples were analysed on a FACSCanto II (BD
Bioscience) and the percentage or the MFI of DyLight 488-positive
DC subsets was determined.
For blocking experiments unlabelled DEC205-specific antibody
(100 mg/ml), unmodified SIINFEKL peptide (15 mM) or
polydT17-G12 ODN (5 mM) was added to the antibody staining
mix 15 minutes prior to addition of conjugates.
To investigate the uptake of conjugates in vivo, mice were
injected with 5–8 mg DyLight 488-labelled conjugates into the
footpad. Popliteal lymph nodes were dissected 6 or 16 h after
conjugate administration and single cell suspension were prepared
by liberase/DNase digest. Cells were stained with antibodies
specific for CD11c, CD8, CD4 and CD3 (all BD Bioscience) in
combination with anti-DEC205 (Miltenyi, Surrey, UK) antibody.
Uptake of conjugate was determined by flow cytometry using a
FACScanto II (BD Bioscience).
Immunisation Studies
Mice were injected with conjugates into the hind footpad. In
some experiments mice were co-injected with 25 mg anti-CD40
antibody (BD Bioscience), 1.5–30 mg soluble S-CpG 1668 ODN,
10 mg soluble CpG or 200 mg anti-DEC205 antibody. Control
mice were injected with PBS. On day 5 or 6 after immunisation,
mice were injected intravenously with 107 target cells consisting of
a 1:1 mixture of SIINFEKL peptide-pulsed splenocytes labelled
with 0.35 mM carboxyfluorescein succinyl ester (CFSE) and
unpulsed splenocytes labelled with 3.5 mm CFSE. To analyse the
in vivo CTL assay, mice were culled the next day and splenocyte
suspensions were prepared by Liberase/DNase (both Roche,
Welwyn Garden City, UK) digestion. The frequencies of the target
cells pulsed with 200 nM peptide or left unpulsed were determined
by flow cytometry for individual mice on a FACSCanto II (BD
Bioscience) and the percentage of antigen-specific killing was
calculated using the following formula: (1-%CFSEpeptide/
%CFSEno peptide)x100.
For ex vivo restimulation of CTL, splenocytes from immunised
mice investigated by in vivo CTL assay were cultured in the
presence of 1 mM SIINFEKL peptide over night. The next day,
cells were incubated for 3 h in the presence of 5 mM Brefeldin
before being harvested and fixed in 4% paraformaldehyde. Cells
were stained with anti-CD8 and anti-Thy1.2 (or alternatively anti-
CD3) antibody followed by intracellular staining of IFNc (all
antibodies from BD Bioscience). The frequency of IFNc-produc-
ing CD8 T cells was determined by flow cytometry.
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Tumor Model
C57BL/6 mice were immunised into the footpad with
conjugates as described above. 30 days after prophylactic
vaccination, 4–56105 B16 melanoma cells expressing an OVA-
GFP fusion protein were injected intravenously [47]. The OVA-
expressing melanoma cell line had been generated earlier from
parental B16 cells obtained from the Cancer Research UK Cell
Service Laboratory by transduction with a VSV-G pseudotyped
retrovirus in combination with single-cell sorting of GFP-positive
cells. For therapeutic vaccination, mice were inoculated with
7.56105 of these OVA-expressing B16 melanoma cells and 6 days
later mice were treated by footpad injection with conjugates as
described above. The number of lung nodules was determined 18
days post tumour challenge with up to 250 nodules being counted
per lung. Photographs of the left upper lobe of lungs fixed in
Fekete’s solution were taken with a Fujifilm S5 Pro camera in
combination with a Tamron 18–250 mm lens.
Statistics
Statistical analysis was performed using a two-tailed Student’s t-
test if not otherwise indicated (Prism Program; Graphpad software,
La Jolla, USA). In the graphs p values are indicated as follows: *
p,0.05; ** p,0.01; *** p,0.0001; n.s. not significant (p.0.05).
Supporting Information
Figure S1 Characterisation of antibody-antigen-adju-
vant conjugates. 2 mg DEC-OVA-CpG conjugate before gel
filtration or 2 mg antibody mixed with 1 mg soluble S-CpG as
control were run on 4–20% gradient SDS gels under non-reducing
conditions. Gels were sequentially stained with Coomassie Blue (A)
and ethidium bromide solution (B) for visualisation of proteins and
nucleic acids, respectively. (C) The ethidium bromide-stained gel
was loaded with 27 mg of DEC-OVA-CpG conjugate after
purification by gel filtration.
(TIF)
Figure S2 Immunisation with antibody-antigen conju-
gates plus soluble adjuvant. C57BL/6 mice were immunised
with 8 mg DEC-OVA or iso1-OVA conjugate with or without
10 mg of soluble CpG 1668 ODN by footpad injection. Control
mice received PBS injections. At day 6 after immunisation, target
cells were injected intravenously. The following day, the in vivo
CTL assay was analysed by flow cytometry. Data are pooled from
3 experiments. The average percentage of antigen-specific target
cell killing for each group is shown as a bar.
(TIF)
Figure S3 Titration of antibodies and conjugates for
staining of DEC205+ DC. CD11c-enriched splenocytes from
C57BL/6 mice were stained with 3–120 nM unlabelled (A, D) or
DyLight-488 labelled (B, C) conjugates. As control cells were
stained with 0.3–120 nM DyLight-488 labelled DEC205-specific
antibody (B). In case of unlabelled conjugates, staining was
performed indirectly using PE-labelled streptavidin which binds to
the biotinylated OVA and OVAlong peptide (A) or by sequential
staining with biotinylated anti-OVA specific antibody followed by
incubation with PE-labelled streptavidin (D). In addition, cells
were stained with CD11c-, CD8a-specific antibodies to distinguish
DC subsets. Binding of conjugate was analysed by flow cytometry
gating on CD8a+ CD11c+ DC. Background staining of CD8a+
DC not incubated with conjugate is shown as solid grey histogram.
Data are representative of two independent experiments.
(TIF)
Figure S4 Blocking of antibody conjugate binding.
CD11c-enriched splenocytes from C57BL/6 mice were incubated
with 30 nM of conjugates in the presence or absence of unlabelled
DEC205 antibody (100 mg/ml), polydT17-G12 (5 mM) or SIIN-
FEKL peptide (15 mM) for blocking of antibody-, nucleic acid- or
peptide-mediated binding of conjugates, respectively. (A) Unla-
belled peptide-containing conjugates were stained with PE-labelled
streptavidin in combination with CD11c- and CD8a-specific
antibodies to distinguish DC subsets. (B) DyLight-488 labelled
conjugates generated with antigen fusion antibodies were used in
combination with CD11c- and CD8a-specific antibodies. Binding
of conjugate was analysed by flow cytometry gating on CD8a+
versus CD8a2 CD11c+ DC. Background staining of DC not
incubated with conjugate is shown as solid grey histogram. Data
are representative of two independent experiments.
(TIF)
Figure S5 Characterisation of antigen fusion antibody-
adjuvant conjugates. 10 mg of untreated antigen fusion
antibody (DEC-Fus) and purified antigen fusion antibody-adjuvant
conjugates (DEC-Fus-CpG and iso-Fus-CpG) were run on 4–20%
gradient SDS gels under non-reducing conditions. The gel was
sequentially stained with Coomassie Blue (A) and ethidium
bromide solution (B) for visualisation of proteins and nucleic
acids, respectively.
(TIF)
Figure S6 Induction of antigen-sepcific killing and anti-
tumour immunity after vaccination with a low dose of
DEC-Fus-CpG conjugate. C57BL/6 mice were immunised
into the footpad with 1 mg of DEC-Fus-CpG conjugate (7 pmol of
antigen) while control mice were injected with PBS. (A) At day 5
after immunisation, in vivo CTL assays were performed by
intravenous injection of target cells. Antigen-specific killing of
target cells was analysed the following day. The depicted data are
pooled from 4 independent experiments. (B) 30 days post
immunisation, OVA-expressing B16 melanoma cells were injected
intravenously and 18 days later, the number of lung nodules was
determined. Data from two independent experiments are shown.
Each symbol representing an individual mouse while the average
antigen-specific killing (A) or number of lung nodules (B) for each
group is depicted as a bar.
(TIF)
Figure S7 Decrease in the size of tumour nodules after
therapeutic intervention. Mice were inoculated intravenously
with OVA-expressing B16 melanoma cells and 6 days later mice
were vaccinated with different doses (7–56 pmol) of DEC-Fus-
CpG or OVA-CpG conjugate by footpad injection. 18 days after
tumour cell injection lungs were harvested, fixed and photographs
of the left upper lobe were taken. The photographs show the lobes
from one representative experiment out of three.
(TIF)
Acknowledgments
We thank David Sancho and Caetano Reis e Sousa for providing OVA-
specific peptides. Antigen antibody fusion constructs were kindly provided
by Ralph Steinman. We also thank Caetano Reis e Sousa for helpful
discussions and critical review of the manuscript.
Author Contributions
Conceived and designed the experiments: MK FN SD. Performed the
experiments: MK BG QH SD. Analyzed the data: MK BG QH SD.
Contributed reagents/materials/analysis tools: RA SU SA FN. Wrote the
Antibody-Antigen-Adjuvant Conjugates
PLoS ONE | www.plosone.org 11 July 2012 | Volume 7 | Issue 7 | e40208
paper: MK BG SD. Provided technical instructions for conjugate
generation and characterisation: RA.
References
1. Caminschi I, Lahoud MH, Shortman K (2009) Enhancing immune responses by
targeting antigen to DC. Eur J Immunol 39: 931–938.
2. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, et al. (2002)
Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the
steady state leads to antigen presentation on major histocompatibility complex class
I products and peripheral CD8+ T cell tolerance. J Exp Med 196: 1627–1638.
3. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, et al. (2004)
In vivo targeting of antigens to maturing dendritic cells via the DEC-205
receptor improves T cell vaccination. J Exp Med 199: 815–824.
4. Wang H, Griffiths MN, Burton DR, Ghazal P (2000) Rapid antibody responses
by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad
Sci U S A 97: 847–852.
5. Demangel C, Zhou J, Choo AB, Shoebridge G, Halliday GM, et al. (2005)
Single chain antibody fragments for the selective targeting of antigens to
dendritic cells. Mol Immunol 42: 979–985.
6. Carter RW, Thompson C, Reid DM, Wong SY, Tough DF (2006) Preferential
induction of CD4+ T cell responses through in vivo targeting of antigen to
dendritic cell-associated C-type lectin-1. J Immunol 177: 2276–2284.
7. Carter RW, Thompson C, Reid DM, Wong SY, Tough DF (2006) Induction of
CD8+ T cell responses through targeting of antigen to Dectin-2. Cell Immunol
239: 87–91.
8. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, et al. (2008) Tumor
therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin.
J Clin Invest 118: 2098–2110.
9. Caminschi I, Proietto AI, Ahmet F, Kitsoulis S, Shin Teh J, et al. (2008) The
dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine
enhancement. Blood 112: 3264–3273.
10. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, et
al. (2007) Differential antigen processing by dendritic cell subsets in vivo. Science
315: 107–111.
11. Idoyaga J, Lubkin A, Fiorese C, Lahoud MH, Caminschi I, et al. (2011)
Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag
p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A.
Proc Natl Acad Sci U S A 108: 2384–2389.
12. Trumpfheller C, Caskey M, Nchinda G, Longhi MP, Mizenina O, et al. (2008)
The microbial mimic poly IC induces durable and protective CD4+ T cell
immunity together with a dendritic cell targeted vaccine. Proc Natl Acad
Sci U S A 105: 2574–2579.
13. Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, et al. (2008) Targeting
the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor
DEC-205 stimulates protective T-cell responses. Blood 112: 1231–1239.
14. Bozzacco L, Trumpfheller C, Huang Y, Longhi MP, Shimeliovich I, et al. (2010)
HIV gag protein is efficiently cross-presented when targeted with an antibody
towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC.
Eur J Immunol 40: 36–46.
15. Mahnke K, Qian Y, Fondel S, Brueck J, Becker C, et al. (2005) Targeting of
antigens to activated dendritic cells in vivo cures metastatic melanoma in mice.
Cancer Res 65: 7007–7012.
16. Johnson TS, Mahnke K, Storn V, Schonfeld K, Ring S, et al. (2008) Inhibition
of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-
205 single-chain fragment variable molecule. Clin Cancer Res 14: 8169–8177.
17. Wang B, Kuroiwa JM, He LZ, Charalambous A, Keler T, et al. (2009) The
human cancer antigen mesothelin is more efficiently presented to the mouse
immune system when targeted to the DEC-205/CD205 receptor on dendritic
cells. Ann N Y Acad Sci 1174: 6–17.
18. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, et al. (2001) Dendritic cells
induce peripheral T cell unresponsiveness under steady state conditions in vivo.
J Exp Med 194: 769–779.
19. Kanzler H, Barrat FJ, Hessel EM, Coffman RL (2007) Therapeutic targeting of
innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13:
552–559.
20. Diebold SS (2008) Determination of T-cell fate by dendritic cells. Immunol Cell
Biol 86: 389–397.
21. Gunzer M, Riemann H, Basoglu Y, Hillmer A, Weishaupt C, et al. (2005)
Systemic administration of a TLR7 ligand leads to transient immune
incompetence due to peripheral-blood leukocyte depletion. Blood 106: 2424–
2432.
22. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, et al. (2004)
Lymphoid follicle destruction and immunosuppression after repeated CpG
oligodeoxynucleotide administration. Nat Med 10: 187–192.
23. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, et al. (2009)
Triggering TLR7 in mice induces immune activation and lymphoid system
disruption, resembling HIV-mediated pathology. Blood 113: 377–388.
24. Maurer T, Heit A, Hochrein H, Ampenberger F, O’Keeffe M, et al. (2002)
CpG-DNA aided cross-presentation of soluble antigens by dendritic cells.
Eur J Immunol 32: 2356–2364.
25. Blander JM, Medzhitov R (2006) Toll-dependent selection of microbial antigens
for presentation by dendritic cells. Nature 440: 808–812.
26. Edwards AD, Diebold SS, Slack EM, Tomizawa H, Hemmi H, et al. (2003)
Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by
CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines.
Eur J Immunol 33: 827–833.
27. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, et al. (2010)
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative
equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 207: 1261–1271.
28. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, et al. (2002) Human TLR7 or
TLR8 independently confer responsiveness to the antiviral compound R-848.
Nat Immunol 3: 499.
29. Roberts TL, Sweet MJ, Hume DA, Stacey KJ (2005) Cutting edge: species-
specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-
modified oligonucleotides. J Immunol 174: 605–608.
30. Waibler Z, Anzaghe M, Konur A, Akira S, Muller W, et al. (2008) Excessive
CpG 1668 stimulation triggers IL-10 production by cDC that inhibits IFN-alpha
responses by pDC. Eur J Immunol 38: 3127–3137.
31. Cho HJ, Takabayashi K, Cheng PM, Nguyen MD, Corr M, et al. (2000)
Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity
by a T-helper cell-independent mechanism. Nat Biotechnol 18: 509–514.
32. Heit A, Maurer T, Hochrein H, Bauer S, Huster KM, et al. (2003) Cutting edge:
Toll-like receptor 9 expression is not required for CpG DNA-aided cross-
presentation of DNA-conjugated antigens but essential for cross-priming of CD8
T cells. J Immunol 170: 2802–2805.
33. Wilson NS, El-Sukkari D, Belz GT, Smith CM, Steptoe RJ, et al. (2003) Most
lymphoid organ dendritic cell types are phenotypically and functionally
immature. Blood 102: 2187–2194.
34. Burgdorf S, Lukacs-Kornek V, Kurts C (2006) The mannose receptor mediates
uptake of soluble but not of cell-associated antigen for cross-presentation.
J Immunol 176: 6770–6776.
35. Burgdorf S, Scholz C, Kautz A, Tampe R, Kurts C (2008) Spatial and
mechanistic separation of cross-presentation and endogenous antigen presenta-
tion. Nat Immunol 9: 558–566.
36. Jiang W, Swiggard WJ, Heufler C, Peng M, Mirza A, et al. (1995) The receptor
DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in
antigen processing. Nature 375: 151–155.
37. Kamphorst AO, Guermonprez P, Dudziak D, Nussenzweig MC (2010) Route of
antigen uptake differentially impacts presentation by dendritic cells and activated
monocytes. J Immunol 185: 3426–3435.
38. Kimura Y, Sonehara K, Kuramoto E, Makino T, Yamamoto S, et al. (1994)
Binding of oligoguanylate to scavenger receptors is required for oligonucleotides
to augment NK cell activity and induce IFN. J Biochem 116: 991–994.
39. Zhu FG, Reich CF, Pisetsky DS (2001) The role of the macrophage scavenger
receptor in immune stimulation by bacterial DNA and synthetic oligonucleo-
tides. Immunology 103: 226–234.
40. Tirapu I, Giquel B, Alexopoulou L, Uematsu S, Flavell R, et al. (2009) PolyI:C-
induced reduction in uptake of soluble antigen is independent of dendritic cell
activation. Int Immunol 21: 871–879.
41. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors
modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443–446.
42. van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG (2004)
Targeting dendritic cells with antigen-containing liposomes: a highly effective
procedure for induction of antitumor immunity and for tumor immunotherapy.
Cancer Res 64: 4357–4365.
43. Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, et al. (2010) Targeted
PLGA nano- but not microparticles specifically deliver antigen to human
dendritic cells via DC-SIGN in vitro. J Control Release 144: 118–126.
44. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, et al.
(2011) Targeted delivery of Toll-like receptor ligands to human and mouse
dendritic cells strongly enhances adjuvanticity. Blood 118: 6836–6844.
45. (1989) UKCCCR guidelines for the welfare of animals in experimental
neoplasia. Cancer Metastasis Rev 8: 82–88.
46. Pear WS, Nolan GP, Scott ML, Baltimore D (1993) Production of high-titer
helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90:
8392–8396.
47. Rajagopal D, Paturel C, Morel Y, Uematsu S, Akira S, et al. (2010)
Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant
activity of Toll-like receptor 7 agonists. Blood 115: 1949–1957.
Antibody-Antigen-Adjuvant Conjugates
PLoS ONE | www.plosone.org 12 July 2012 | Volume 7 | Issue 7 | e40208
